AUSTIN, Texas & CAMBRIDGE, Mass.— (October 7, 2019) — Genprex, Inc.(NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. A recently published paper by researchers in Australia, Spain and Austria […]